AHG vs HCM

For growth investors, Akso Health Group (AHG) is the stronger pick with 512.

1% revenue growth year-over-year, versus -24. 8% for HUTCHMED (China) Limited (HCM). HUTCHMED (China) Limited (HCM) offers the better valuation at 60. 5x trailing P/E (41. 7x forward), making it the more compelling value choice. Analysts rate HUTCHMED (China) Limited (HCM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Akso Health Group is actually cheaper at 0.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Akso Health Group (AHG) delivered a total return of +42.

4%, compared to -49. 3% for HUTCHMED (China) Limited (HCM). Over 10 years, the gap is even starker: HCM returned +1. 0% versus AHG's -97. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akso Health Group (AHG) is the lower-risk stock at 0.

14β versus HUTCHMED (China) Limited's 0. 66β — meaning HCM is approximately 364% more volatile than AHG relative to the S&P 500. On balance sheet safety, Akso Health Group (AHG) carries a lower debt/equity ratio of 0% versus 12% for HUTCHMED (China) Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akso Health Group (AHG) is pulling ahead at 512.

1% versus -24. 8% for HUTCHMED (China) Limited (HCM). On earnings-per-share growth, the picture is similar: Akso Health Group grew EPS -23. 1% year-over-year, compared to -63. 3% for HUTCHMED (China) Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HUTCHMED (China) Limited (HCM) is the more profitable company, earning 6.

0% net margin versus -913. 4% for Akso Health Group — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCM leads at -6. 9% versus -1125. 4% for AHG. At the gross margin level — before operating expenses — HCM leads at 44. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Akso Health Group (AHG) trades at 0.

5x forward P/E versus 41. 7x for HUTCHMED (China) Limited — 41. 1x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Akso Health Group (AHG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

14)). Both have compounded well over 10 years (AHG: -97. 1%, HCM: +1. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AHG (Financial Services) and HCM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AHG is a small-cap high-growth stock; HCM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.